Pimavanserin for the treatment of Parkinson's disease psychosis
Authors:
- 6 September 2013
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 14 (14) , 1969-1975
Abstract
(2013). Pimavanserin for the treatment of Parkinson's disease psychosis. Expert Opinion on Pharmacotherapy: Vol. 14, No. 14, pp. 1969-1975. doi: 10.1517/14656566.2013.819345Keywords
This publication has 35 references indexed in Scilit:
- Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/daySchizophrenia Research, 2012
- Psychiatric syndromes in Parkinson's diseaseCurrent Opinion in Psychiatry, 2012
- Serotonin Receptors as Targets for Drugs Useful to Treat Psychosis and Cognitive Impairment in SchizophreniaCurrent Pharmaceutical Biotechnology, 2012
- Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's diseaseBehavioural Pharmacology, 2011
- Parkinson's disease: The quintessential neuropsychiatric disorderMovement Disorders, 2011
- Pimavanserin tartrate, a 5-HT2A receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteersSleep Medicine, 2011
- Inverse agonism and its therapeutic significanceIndian Journal of Pharmacology, 2011
- Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disordersExpert Opinion on Pharmacotherapy, 2008
- 5-HT2A Inverse-Agonists for the Treatment of InsomniaCurrent Topics in Medicinal Chemistry, 2008
- Pharmacological and Behavioral Profile of N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl) Carbamide (2 R,3 R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5-Hydroxytryptamine2A Receptor Inverse AgonistThe Journal of Pharmacology and Experimental Therapeutics, 2006